华图山鼎设计股份有限公司 关于股份回购进展的公告 证券代码：300492 证券简称：华图山鼎 公告编号：2025-035 二、其他说明 公司后续将根据市场情况在回购期限内继续实施本次回购计划，并根据相关 法律法规和规范性文件的规定及时履行信息披露义务。敬请广大投资者注意投资 1 风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华图山鼎设计股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 了第五届董事会第三次会议，审议通过了《关于回购公司股份方案的议案》，同 意拟使用公司自有资金或自筹资金通过集中竞价交易方式回购公司部分股份用 于实施股权激励或员工持股计划。本次回购股份资金总额为不低于人民币 2.25 亿元，不超过人民币 4.50 亿元（均包含本数），最终具体回购资金总额以回购期 限届满时实际回购的资金总额为准；回购价格不高于公司董事会审议通过回购股 份决议前 30 个交易日公司股票交易均价的 150%，上限为 127.91 元/股；回购股 份实施期限自董事会审议通过本次回购股份方案之日起 12 个月内。具体内容详 见公司于 202 ...

Group 1 - The company has received a loan commitment letter from CITIC Bank Chengdu Branch, promising to provide up to 300 million yuan for stock repurchase purposes [1] - The loan has a term of up to 36 months and is specifically designated for the repurchase of the company's shares [1] - The commitment letter does not guarantee the amount of shares to be repurchased, as the actual repurchase amount will be determined based on market conditions [1]

证券代码：300492 证券简称：华图山鼎 公告编号：2025-034 华图山鼎设计股份有限公司 关于取得金融机构贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、回购股份方案的基本情况 2、本次取得《贷款承诺函》，不代表公司对回购金额的承诺，具体回购股票 金额以回购实施完成时实际回购的金额为准。 3、公司将严格按照《上市公司股份回购规则》《深圳证券交易所上市公司自 1 华图山鼎设计股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 了第五届董事会第三次会议，审议通过了《关于回购公司股份方案的议案》，同 意拟使用公司自有资金或自筹资金通过集中竞价交易方式回购公司部分股份用 于实施股权激励或员工持股计划。本次回购股份资金总额为不低于人民币 2.25 亿元，不超过人民币 4.50 亿元（均包含本数），最终具体回购资金总额以回购期 限届满时实际回购的资金总额为准；回购价格不高于公司董事会审议通过回购股 份决议前 30 个交易日公司股票交易均价的 150%，上限为 127.91 元/股；回购股 份实施期限自董事会审议通过本次回购 ...

证券代码：300492 证券简称：华图山鼎 公告编号：2025-033 华图山鼎设计股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 3、公司向中国证券登记结算有限责任公司深圳分公司就核查对象在自查期 间买卖公司股票情况进行了查询确认，并由中国证券登记结算有限责任公司深圳 分公司出具了《信息披露义务人持股及股份变更查询证明》和《股东股份变更明 细清单》。 二、核查对象在自查期间买卖公司股票的情况 根据中国证券登记结算有限责任公司深圳分公司出具的《信息披露义务人持 股及股份变更查询证明》及《股东股份变更明细清单》，在激励计划自查期间， 核查对象买卖公司股票的情况如下： 经核查，在自查期间，共有 1 名核查对象交易过本公司股票，其在买卖公司 股票前未知悉本激励计划的相关信息，亦未有任何人员向其泄露公司本次激励计 划的具体信息或基于相关信息建议其买卖公司股票，其在自查期间进行的股票交 易系基于个人对二级市场交易情况的独立判断而进行的操作，不存在利用激励计 划相关内幕信息进行公司股票交易的情形。 三、结论 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假 ...

证券代码：300492 证券简称：华图山鼎 华图山鼎设计股份有限公司 2025 年员工持股计划 本方案主要条款与公司 2025 年 4 月 29 日公告的员工持股计划草案及其摘要内容一致 华图山鼎设计股份有限公司 二○二五年五月 声明 本公司及董事会全体成员保证本持股计划内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 1 风险提示 1、华图山鼎设计股份有限公司（以下简称"华图山鼎"、"公司"或"本公司"） 2025年员工持股计划（以下简称"员工持股计划"、"本员工持股计划"）已获得股东 大会批准，具体资金来源、出资比例、实施方案等属初步结果，能否完成实施，存在不 确定性。 2、若员工认购资金不足，本持股计划存在低于预计规模的风险。 3、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注意投资 风险。 2 特别提示 1、华图山鼎设计股份有限公司（以下简称"华图山鼎"或"公司"）2025年员工持股计 划（以下简称"本持股计划"）系公司依据《中华人民共和国公司法》《中华人民共和国 证券法》《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所上市公 司自律监管指引第2号——创业板上 ...

北京市竞天公诚律师事务所 关于华图山鼎设计股份有限公司 2024 年年度股东大会的 中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于华图山鼎设计股份有限公司 2024 年年度股东大会的法律意见书 致：华图山鼎设计股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）受华图山鼎设计股份有 限公司（以下简称"公司"）的委托，根据和参照《中华人民共和国公司法》 （以下称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）和 中国证券监督管理委员会发布的《上市公司股东会规则》（以下称"《规 则》"）等有关规定，就公司召开的 2024 年年度股东大会（以下称"本次股东 大会"）的有关事宜，出具本法律意见书。 为了出具本法律意见书，本所审查了公司提供的有关本次股东大会的如下 文件的原件或复印件： 二○二五年五月三十日 法律意见书 中国 北京 1、现场出席本次股东大会的有关股东、股东授权代表、董事、监事及其他 有关人员的身份证明及/或授权委托书； 2、公司董事会向本次股东 ...

证券代码：300492 证券简称：华图山鼎 公告编号：2025-032 华图山鼎设计股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）股东大会届次：2024 年年度股东大会 公司董事会以公告方式向全体股东发出召开 2024 年年度股东大会的通知，详见 2025 年 4 月 29 日公司在巨潮资讯网（www.cninfo.com.cn）刊登的《关于召开 2024 年年度股东大会 通知的公告》（公告编号：2025-026）。 （二）会议召集人：公司董事会 （三）会议主持人：董事长吴正杲先生 （四）会议召开时间： 1、现场会议时间：2025 年 5 月 30 日（星期五）14:00 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 30 日交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网 投票系 ...

Core Viewpoint - The former actual controller of Huatu Shanding, Che Lu, plans to reduce his stake in the company by up to 3%, potentially cashing out approximately 386 million yuan, indicating a trend of significant share reductions by the former controller amid concerns about the company's performance [2][5][10]. Group 1: Shareholding and Reduction Plans - Che Lu currently holds 16.53% of Huatu Shanding's shares, making him the second-largest shareholder [4][6]. - This planned reduction marks Che Lu's fourth attempt to cash out, with the latest reduction scheduled between June 19 and September 18, 2025 [4][6]. - The shares Che Lu intends to sell are sourced from shares acquired before the company's IPO and from capital reserve conversions [4]. Group 2: Financial Performance and Market Context - Huatu Shanding's core business includes non-degree training and architectural design, with non-degree training being the primary focus [3][10]. - The company has faced poor performance since its change of ownership in 2019, with a notable decline in revenue and profits until a recent recovery in 2024, where revenue increased by 1046.34% year-on-year [10][11]. - In the first quarter of 2024, the company reported a revenue of 828 million yuan and a net profit of 121 million yuan, marking significant growth compared to previous years [11]. Group 3: Historical Context and Ownership Changes - Huatu Shanding was formerly known as Shanding Design and underwent a change in control in 2019, leading to a significant ownership transfer and a rebranding to Huatu Shanding [6][7]. - The ownership transition involved a complex arrangement where Huatu Education's assets were effectively injected into Huatu Shanding, aiming to pivot the company's focus towards education [10][11]. - Che Lu has previously cashed out significant amounts, totaling nearly 800 million yuan through various share reductions since the company's ownership change [9].

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Group 1: Company Leadership Changes - Longi Green Energy announced that Li Zhenguo will resign from the positions of General Manager and Legal Representative to focus on R&D and technology management, while continuing as the head of the Central Research Institute and Chief Technology Officer [2] - The company appointed Zhong Baoshan as the new General Manager, and this leadership change is not expected to impact the company's operations [2] Group 2: Contracts and Agreements - Pingzhi Information signed an AI computing power technology service framework agreement with China Telecom's Shaanxi branch, with a total contract value of approximately 246 million yuan [3] - The actual execution amount will depend on specific orders, and the agreement is not expected to have a significant impact on the company's annual performance [3] Group 3: Share Issuance and Stock Transactions - *ST Songfa announced the issuance of 738 million new shares at a price of 10.16 yuan per share for asset acquisition [5] - Shenghong Technology set the preliminary inquiry transfer price at 65.85 yuan per share, with 24 institutional investors participating in the inquiry [3] Group 4: Shareholder Actions - Xinhua Medical's controlling shareholder plans to increase holdings by 100 million to 200 million yuan [6] - Several companies, including Yongmaotai and Green Harmony, announced plans for share reductions by up to 3% of total shares [6] Group 5: Corporate Developments - Rongsheng Environmental Protection reported that its controlling shareholder, Feng Ronghua, has been taken into custody by law enforcement, but this matter is unrelated to the company [4] - Chongqing Steel terminated the absorption merger with its wholly-owned subsidiary [7]